Neurogait
Using AI to screen Curable Dementia and other Neurological disease
Company Overview
Snapshot
Founded in July 2019 by Eyal Fruchtman and Ben Francke, Neurogait operates with 1–10 employees. The company has secured one funding round and is actively conducting clinical pilots in Germany, signaling its progress in product development and market validation.
Business overview
Neurogait is a Health Tech & Life Sciences company focused on developing AI-based clinical screenings for neurodegenerative diseases, including curable dementia and Parkinson's. The company's core technology leverages artificial intelligence, deep learning, computer vision, and machine learning to provide diagnostic devices and digital medical diagnostics. Neurogait serves the healthcare market, targeting both providers and patients, with a particular focus on the medical devices industry in North America, Europe, and Asia.
Strategic signal
In January 2022, Neurogait was highlighted for creating an AI-based ecosystem for neurological diseases. This development is significant as it demonstrates the company's commitment to leveraging advanced technology to address critical health challenges, signaling to investors a strong potential for growth and impact in the digital health and medical technologies sector.
Log in to access full profile ›Company Intelligence Q&A
- What is Neurogait's primary focus?
- Neurogait focuses on developing AI-based clinical screenings for neurodegenerative diseases, such as curable dementia and Parkinson's.
- When was Neurogait founded and by whom?
- Neurogait was founded in July 2019 by Co-founders Eyal Fruchtman and Ben Francke.
- What is the current employee size of Neurogait?
- Neurogait currently has 1–10 employees.
- What is Neurogait's product development status?
- Neurogait is currently conducting clinical pilots in Germany and is working on regulatory approvals for its solution.
- What significant market activity has Neurogait engaged in recently?
- In January 2022, Neurogait was noted for creating an AI-based ecosystem for neurological diseases, indicating its strategic direction in the health tech sector.